Orgenesis has filed a patent for a composition that includes ribonucleases and bioxomes, exosomes, or a combination of both. The composition is intended for the treatment and prevention of viral diseases, including Covid-19. The patent also covers the use of immune cells and ribonucleases in the formulation for treating the disease. GlobalData’s report on Orgenesis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orgenesis, NSAID cancer drugs was a key innovation area identified from patents. Orgenesis's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment for viral diseases using ribonucleases and bioxomes/exosomes
A recently filed patent (Publication Number: US20230147602A1) describes a composition that includes a ribonuclease and a bioxome, exosome, or a combination of the two. The ribonuclease can be selected from a group of ribonucleases such as RNase A, RNase H, RNase III, and others. One specific ribonuclease mentioned is ranpirnase.
The composition is intended for use in treating viral diseases, including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), adenovirus, herpesvirus, papillomavirus, and many others. The composition can be used to treat a wide range of viral diseases, including acute hepatitis, AIDS, bronchiolitis, chickenpox, common cold, influenza, measles, and more. Specifically, the composition can be used to treat Covid-19, caused by SARS-CoV-2.
The patent also mentions the possibility of including immunoglobulins, fragments thereof, antibodies, or combinations thereof obtained from a plasma of a subject immune to the viral disease in the composition. Additionally, immune cells can be added to the composition.
The composition can be formulated as a pharmaceutical composition with an excipient and can be delivered through various routes such as intravenous, oral, intranasal, pulmonary, transdermal, and others.
The patent also describes a method for treating viral diseases in a subject by administering the composition. The method involves administering the composition, which includes a ribonuclease, to a subject in need of treatment. The ribonuclease can be selected from the same group mentioned earlier, including ranpirnase. The viral disease can be any of the mentioned diseases, including Covid-19.
The composition can be administered through various routes, including intravenous, oral, intranasal, pulmonary, transdermal, and others.
In summary, the patent describes a composition comprising a ribonuclease and a bioxome, exosome, or a combination thereof, for the treatment of viral diseases. The composition can be used to treat a wide range of viral diseases, including Covid-19. The patent also mentions the possibility of including immunoglobulins and immune cells in the composition. The composition can be formulated as a pharmaceutical composition and administered through various routes. The patent also describes methods for treating viral diseases using the composition.
To know more about GlobalData’s detailed insights on Orgenesis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
